Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2019

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2019

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2019, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 3, 3, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
- The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Uterine Leiomyoma (Uterine Fibroids) - Overview
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Allergan Plc, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Auritec Pharmaceuticals Inc, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by GeneScience Pharmaceuticals Co Ltd, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Immunitor Inc, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Ogeda SA, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Richter Gedeon Nyrt, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2019
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2019

List Of Figures


Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2019

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2019Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2019, provides an overview

USD 2000 View Report

Global High-Intensity Focused Ultrasound Market Size study, by Type (Ultrasound-Guided, MR-Guided), by Application (Prostate Cancer, Body Tumour and Soft Tissue and Uterine Fibroids) and Regional Forecasts 2018-2025

Global High-Intensity Focused Ultrasound Market to reach USD 9.5 billion by 2025.Global High-Intensity Focused Ultrasound Market valued approximately USD 6.0 billion in 2017 is anticipated to grow with a healthy

USD 3950 View Report

Uterine Leiomyoma (Uterine Fibroids) - Market Insight, Epidemiology and Market Forecast - 2028

Uterine Leiomyoma (Uterine Fibroids) - Market Insight, Epidemiology and Market Forecast - 2028 report provides a detailed analysis of the Uterine Leiomyoma (Uterine Fibroids) epidemiology and market

USD 6250 View Report

Uterine Leiomyoma (Uterine Fibroids) - Epidemiology Forecast to 2028

Uterine Leiomyoma (Uterine Fibroids) - Epidemiology Forecast, 2028 report provides a comprehensive analysis of the Uterine Leiomyoma (Uterine Fibroids) epidemiology, providing the historical and forecasted

USD 3250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available